News & Events
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
Additional analyses of data from AURORA, as well as the full adult data set from BEACON Updated data from the ongoing Phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia, including a larger data set and longer follow-up, to be shared in a poster Preliminary data on safety and
More News
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from...
read more
Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 Initiated APOLLO, a confirmatory clinical trial...
read more